Blueprint Medicines EBITDA vs. Revenue
| BPMC Stock | USD 96.38 1.28 1.35% |
EBITDA | First Reported 2010-12-31 | Previous Quarter -470.4 M | Current Value -446.8 M | Quarterly Volatility 252.8 M |
For Blueprint Medicines profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Blueprint Medicines to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Blueprint Medicines Corp utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Blueprint Medicines's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Blueprint Medicines Corp over time as well as its relative position and ranking within its peers.
Blueprint |
Blueprint Medicines' Revenue Breakdown by Earning Segment
Check out Trending Equities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Blueprint Medicines. If investors know Blueprint will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Blueprint Medicines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.09) | Revenue Per Share 6.986 | Quarterly Revenue Growth 1.266 | Return On Assets (0.15) | Return On Equity (0.50) |
The market value of Blueprint Medicines Corp is measured differently than its book value, which is the value of Blueprint that is recorded on the company's balance sheet. Investors also form their own opinion of Blueprint Medicines' value that differs from its market value or its book value, called intrinsic value, which is Blueprint Medicines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Blueprint Medicines' market value can be influenced by many factors that don't directly affect Blueprint Medicines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Blueprint Medicines' value and its price as these two are different measures arrived at by different means. Investors typically determine if Blueprint Medicines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Blueprint Medicines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Blueprint Medicines Corp Revenue vs. EBITDA Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Blueprint Medicines's current stock value. Our valuation model uses many indicators to compare Blueprint Medicines value to that of its competitors to determine the firm's financial worth. Blueprint Medicines Corp is rated below average in ebitda category among its peers. It is rated fourth in revenue category among its peers . At present, Blueprint Medicines' EBITDA is projected to decrease significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Blueprint Medicines' earnings, one of the primary drivers of an investment's value.Blueprint Medicines' Earnings Breakdown by Geography
Blueprint Revenue vs. EBITDA
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Blueprint Medicines |
| = | (470.36 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Blueprint Medicines |
| = | 249.38 M |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Blueprint Revenue vs Competition
Blueprint Medicines Corp is rated fourth in revenue category among its peers. Market size based on revenue of Health Care industry is currently estimated at about 1.92 Billion. Blueprint Medicines retains roughly 249.38 Million in revenue claiming about 13% of equities under Health Care industry.
Blueprint Medicines Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Blueprint Medicines, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Blueprint Medicines will eventually generate negative long term returns. The profitability progress is the general direction of Blueprint Medicines' change in net profit over the period of time. It can combine multiple indicators of Blueprint Medicines, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -3.5 M | -3.7 M | |
| Operating Income | -486.3 M | -462 M | |
| Income Before Tax | -506 M | -480.7 M | |
| Total Other Income Expense Net | -19.7 M | -18.8 M | |
| Net Loss | -507 M | -481.6 M | |
| Income Tax Expense | 968 K | 1 M | |
| Net Loss | -554.7 M | -527 M | |
| Net Loss | -501.8 M | -476.7 M | |
| Interest Income | 15.8 M | 16.6 M | |
| Non Operating Income Net Other | 1.8 M | 1.4 M | |
| Net Interest Income | -22.9 M | -21.7 M | |
| Change To Netincome | 135 M | 141.8 M | |
| Net Loss | (8.37) | (8.79) | |
| Income Quality | 0.86 | 0.62 | |
| Net Income Per E B T | 1.00 | 0.79 |
Blueprint Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Blueprint Medicines. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Blueprint Medicines position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Blueprint Medicines' important profitability drivers and their relationship over time.
Use Blueprint Medicines in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Blueprint Medicines position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Blueprint Medicines will appreciate offsetting losses from the drop in the long position's value.Blueprint Medicines Pair Trading
Blueprint Medicines Corp Pair Trading Analysis
The ability to find closely correlated positions to Blueprint Medicines could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Blueprint Medicines when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Blueprint Medicines - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Blueprint Medicines Corp to buy it.
The correlation of Blueprint Medicines is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Blueprint Medicines moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Blueprint Medicines Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Blueprint Medicines can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Blueprint Medicines position
In addition to having Blueprint Medicines in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Strategy ETFs Thematic Idea Now
Strategy ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Strategy ETFs theme has 1282 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Strategy ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
To fully project Blueprint Medicines' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Blueprint Medicines Corp at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Blueprint Medicines' income statement, its balance sheet, and the statement of cash flows.